Galapagos exercises co-promotion option for filgotinib with collaboration partner Gilead Sciences in eight European countries
Equity lock-up and standstill arrangement between the companies to expire on 31 December 2017 Mechelen, Belgium; 14 December 2017; 22.01 CET - Galapagos NV (Euronext & NASDAQ: GLPG) announced today the decision to opt-in on the co-promotion of …